1. What poor prognostic factors indicate severe PsA disease?
2. How should treatment decisions be approached given the conditional nature of many recommendations?
3. How does long-term damage, such as joint deformities or vision loss, influence treatment decisions in psoriatic arthritis?
4. What are the poor prognostic factors that help define severe psoriatic arthritis?
5. What is the recommended treatment strategy for PsA patients with predominant enthesitis who are both OSM- and biologic-naive?
6. How is active psoriatic arthritis (PsA) defined according to the clinical guideline?
7. Qual é a utilidade do índice PASI na avaliação da gravidade da psoríase em pacientes com PsA?
8. Why are all recommendations regarding switching biologics in active PsA considered conditional and based on very-low-quality evidence?
9. Which oral small molecules are considered in PsA treatment guidelines, and how is tofacitinib categorized differently?
10. Quais manifestações extraarticulares podem estar associadas à artrite psoriásica ativa?
11. Describe the typical patterns of peripheral arthritis distribution seen in PsA.
12. Quais são alguns exemplos de fatores prognósticos ruins na artrite psoriásica?
13. What biologic therapies are recommended for active PsA patients with concomitant active inflammatory bowel disease (IBD)?
14. ¿Qué criterios se utilizan para decidir el cambio de tratamiento en pacientes con PsA activa a pesar del tratamiento con un OSM?
15. Em quais situações pode-se considerar a troca de um TNFi por um inibidor de IL-17 (IL-17i)?
16. Quais são as recomendações para a transição entre diferentes classes de biológicos em pacientes com resposta parcial ou falha primária ao tratamento atual?
17. For patients with active PsA and predominant enthesitis who are treatment-naive, what is the initial recommended therapy?
18. Why is etanercept not recommended as a first-line TNFi biologic in PsA patients with active IBD?
19. What clinical features are included in the assessment of PsA severity?
20. Under what circumstances might switching from an IL-17 inhibitor to an IL-12/23 inhibitor be considered instead of switching to a TNF inhibitor?